{"id":"https://openalex.org/W7199200990","doi":null,"title":"Efficacy and safety of therapeutic strategies against amyloid-\u00df peptides in Alzheimer\u2019s disease: a systematic review and web application-based meta-analysis of large phase III clinical trials","display_name":"Efficacy and safety of therapeutic strategies against amyloid-\u00df peptides in Alzheimer\u2019s disease: a systematic review and web application-based meta-analysis of large phase III clinical trials","alternate_titles":[],"publication_year":2024,"publication_date":"2024-01-01","ids":{"openalex":"https://openalex.org/W7199200990"},"language":"en","primary_location":{"id":"pmh:oai:ruidera.uclm.es:10578/36214","doi":null,"is_oa":true,"landing_page_url":"https://hdl.handle.net/10578/36214","pdf_url":null,"source":{"id":"https://openalex.org/S4377196358","display_name":"RUIdeRA - Institutional University Repository (University of Castilla-La Mancha)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I79189158","host_organization_name":"University of Castilla-La Mancha","host_organization_lineage":["https://openalex.org/I79189158"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/doctoralThesis"},"parent_works":[],"lineage":["https://openalex.org/W7199200990"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://hdl.handle.net/10578/36214","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5085883910","display_name":"Danko Jeremic","orcid":"https://orcid.org/0000-0001-9495-972X","observed_orcids":["https://orcid.org/0000-0001-9495-972X"]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Jeremic, Danko","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5085883910"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.9789999723434448},{"id":"https://openalex.org/keywords/amyloid-beta","display_name":"amyloid-beta","score":0.9409999847412109},{"id":"https://openalex.org/keywords/anti-amyloid-monoclonal-antibodies","display_name":"anti-amyloid monoclonal antibodies","score":0.9700000286102295},{"id":"https://openalex.org/keywords/aducanumab","display_name":"aducanumab","score":0.9710000157356262},{"id":"https://openalex.org/keywords/lecanemab","display_name":"lecanemab","score":1.0},{"id":"https://openalex.org/keywords/amyloid-hypothesis","display_name":"amyloid hypothesis","score":0.7739999890327454},{"id":"https://openalex.org/keywords/drug-efficacy","display_name":"drug efficacy","score":0.4830000102519989},{"id":"https://openalex.org/keywords/adverse-effects","display_name":"adverse effects","score":0.6940000057220459},{"id":"https://openalex.org/keywords/cerebral-edema","display_name":"cerebral edema","score":0.8629999756813049},{"id":"https://openalex.org/keywords/microbleeds","display_name":"microbleeds","score":0.8119999766349792},{"id":"https://openalex.org/keywords/hemosiderosis","display_name":"hemosiderosis","score":0.8899999856948853},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.628000020980835},{"id":"https://openalex.org/keywords/early-intervention","display_name":"early intervention","score":0.46399998664855957},{"id":"https://openalex.org/keywords/neurodegeneration","display_name":"neurodegeneration","score":0.5230000019073486}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7940000295639038},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.7649000287055969},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.6089000105857849},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5630999803543091},{"id":"https://openalex.org/C2779483572","wikidata":"https://www.wikidata.org/wiki/Q83030","display_name":"Dementia","level":3,"score":0.5281000137329102},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.4909999966621399},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.45719999074935913},{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.4034999907016754},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.39489999413490295},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.38449999690055847},{"id":"https://openalex.org/C3018890749","wikidata":"https://www.wikidata.org/wiki/Q204711","display_name":"Food and drug administration","level":2,"score":0.3718000054359436},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.3686999976634979},{"id":"https://openalex.org/C2776925932","wikidata":"https://www.wikidata.org/wiki/Q1755122","display_name":"Neurodegeneration","level":3,"score":0.3659999966621399},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.34869998693466187},{"id":"https://openalex.org/C2992293740","wikidata":"https://www.wikidata.org/wiki/Q4781752","display_name":"Drug approval","level":3,"score":0.3407000005245209},{"id":"https://openalex.org/C2992672634","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Drug trial","level":3,"score":0.3379000127315521},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.3319999873638153},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.313400000333786},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.29809999465942383},{"id":"https://openalex.org/C2777633098","wikidata":"https://www.wikidata.org/wiki/Q2736051","display_name":"Amyloid (mycology)","level":2,"score":0.28610000014305115},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.2784000039100647},{"id":"https://openalex.org/C2992053201","wikidata":"https://www.wikidata.org/wiki/Q2585693","display_name":"Clinical efficacy","level":2,"score":0.2630000114440918},{"id":"https://openalex.org/C502032728","wikidata":"https://www.wikidata.org/wiki/Q11081","display_name":"Alzheimer's disease","level":3,"score":0.26159998774528503},{"id":"https://openalex.org/C2779974597","wikidata":"https://www.wikidata.org/wiki/Q28448986","display_name":"Clinical Practice","level":2,"score":0.260699987411499},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.25679999589920044}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:ruidera.uclm.es:10578/36214","doi":null,"is_oa":true,"landing_page_url":"https://hdl.handle.net/10578/36214","pdf_url":null,"source":{"id":"https://openalex.org/S4377196358","display_name":"RUIdeRA - Institutional University Repository (University of Castilla-La Mancha)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I79189158","host_organization_name":"University of Castilla-La Mancha","host_organization_lineage":["https://openalex.org/I79189158"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/doctoralThesis"}],"best_oa_location":{"id":"pmh:oai:ruidera.uclm.es:10578/36214","doi":null,"is_oa":true,"landing_page_url":"https://hdl.handle.net/10578/36214","pdf_url":null,"source":{"id":"https://openalex.org/S4377196358","display_name":"RUIdeRA - Institutional University Repository (University of Castilla-La Mancha)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I79189158","host_organization_name":"University of Castilla-La Mancha","host_organization_lineage":["https://openalex.org/I79189158"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/doctoralThesis"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/systematic-review","display_name":"Systematic Review"},{"id":"https://openalex.org/study-designs/meta-analysis","display_name":"Meta-Analysis"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4380884053","https://openalex.org/W2965520785","https://openalex.org/W6903528755","https://openalex.org/W3209578655","https://openalex.org/W4205705947","https://openalex.org/W4388688083","https://openalex.org/W4387021628","https://openalex.org/W4387440386","https://openalex.org/W4386045911","https://openalex.org/W4321021390"],"abstract_inverted_index":{"Alzheimer":[0],"disease":[1,20],"(AD)":[2],"is":[3,15,40,236,377],"a":[4,247,316,362],"big":[5],"problem":[6],"for":[7,29,161,234,250],"the":[8,16,24,44,125,135,142,167,217,229,322,391,415,455,462,534],"scientific":[9],"community":[10],"and":[11,23,55,65,69,86,131,137,147,179,187,252,273,284,299,324,354,365,382,387,411,444,461,475,494,518,533,549,559,576,586],"our":[12,465,521],"societies.":[13],"It":[14],"most":[17,25,456],"common":[18,26],"neurodegenerative":[19],"in":[21,104,124,141,163,241,280,318,330,345,373,390,439,570],"aging":[22],"dementia,":[27],"accounting":[28],"an":[30,366],"estimated":[31,237],"60-80%":[32],"of":[33,46,57,128,219,262,310,326,369,446,464,492,502,511,537],"all":[34,183],"dementia":[35],"cases":[36],"(Alzheimer's_Association,":[37],"2021).":[38],"There":[39],"no":[41,157,433],"agreement":[42],"on":[43,210,277,303,420,563],"cause":[45],"this":[47,263,357,359],"disease.":[48],"The":[49,169,338,375,478],"prevailing":[50],"hypothesis":[51,101],"posits":[52],"that":[53,76,115,216,314,396,423,468,524,545,579],"misfolding":[54],"aggregation":[56],"amyloid-beta":[58],"(A\u00df)":[59],"peptides":[60],"lead":[61,87],"to":[62,88,155,204,238,282,320,406,531,567],"tau":[63,495,582],"deposition":[64],"subsequent":[66],"progressive":[67],"neurodegeneration":[68],"cognitive":[70,479,499],"impairment.":[71],"Therefore,":[72],"it":[73,214],"was":[74,102],"thought":[75],"drugs":[77,174,398,470,507],"targeting":[78,399],"toxic":[79],"A\u00df":[80,117,328,400,426,447,493,550],"species":[81],"could":[82],"reduce":[83,408],"their":[84,286],"accumulation":[85],"clinical":[89,107,177,270,288,336,416],"improvement":[90],"(Panza,":[91],"Lozupone,":[92],"Logroscino,":[93],"&":[94,119],"Imbimbo,":[95],"2019).":[96],"In":[97],"recent":[98,267,440],"years,":[99,441],"amyloid":[100],"tested":[103],"phase":[105,199,231,334],"III":[106,335],"trials":[108,201,417],"with":[109,295,425,484,556],"several":[110],"potent":[111],"monoclonal":[112],"antibodies":[113],"(mAbs)":[114],"target":[116],"(Plotkin":[118],"Cashman,":[120],"2020).":[121],"This":[122],"resulted":[123],"accelerated":[126],"approval":[127],"aducanumab":[129],"(Aduhelm\u00ae)":[130],"lecanemab":[132],"(Leqembi\u00ae)":[133],"by":[134,490],"Food":[136],"Drug":[138],"Administration":[139],"(FDA)":[140],"U.S.,":[143],"raising":[144],"both":[145],"hopes":[146],"controversies":[148],"(Elisabeth":[149],"Mahase;":[150],"E.":[151],"Mahase,":[152],"2023).":[153,197],"Up":[154],"date,":[156],"mAbs":[158,329,452,540],"are":[159,175,202,292],"authorized":[160],"use":[162],"AD":[164,305,343,412,547],"patients":[165,251,344],"outside":[166],"U.S.":[168],"main":[170],"concerns":[171],"surrounding":[172],"these":[173,211,220,429,469,506],"questionable":[176],"efficacy":[178,323],"adverse":[180],"effects,":[181],"above":[182],"cerebral":[184,516],"edema,":[185],"microbleeds":[186,517],"hemosiderosis":[188],"(Cummings,":[189],"Aisen,":[190],"et":[191,195,257],"al.,":[192,196,258],"2021;":[193],"Cummings":[194],"Ongoing":[198],"IV":[200,232],"expected":[203],"give":[205],"us":[206],"more":[207],"complete":[208],"picture":[209],"drugs,":[212,279],"however,":[213],"seems":[215],"results":[218,458,463],"studies":[221,275,347],"will":[222],"not":[223,403],"be":[224,239,384,488,554],"available":[225,379],"soon.":[226],"For":[227],"instance,":[228],"confirmatory":[230],"trial":[233],"Aduhelm\u00ae":[235],"completed":[240],"three":[242],"years":[243],"from":[244],"now,":[245],"leaving":[246],"large":[248],"uncertainty":[249],"healthcare":[253],"professionals":[254],"(J.":[255],"Murphy":[256],"2022).":[259],"Part":[260,307],"I":[261],"work":[264,360],"systematically":[265],"reviews":[266],"(from":[268],"2014)":[269],"trials,":[271],"follow-up":[272],"review":[274],"focused":[276,419],"anti-A\u00df":[278,525,539],"order":[281],"summarize":[283],"analyze":[285],"current":[287,538],"potential.":[289],"Promising":[290],"therapies":[291,552],"ighlighted":[293],"together":[294],"newly":[296],"developed":[297,438],"biomarkers":[298,491,558],"therapeutic":[300,371],"strategies":[301,430,561],"acting":[302,562],"early":[304,546,569],"changes.":[306,588],"II":[308],"consists":[309],"web-based":[311],"application,":[312],"AlzMeta.app,":[313],"performs":[315],"meta-analysis":[317,339,466],"R":[319],"evaluate":[321],"safety":[325],"anti-":[327],"large,":[331],"randomized":[332],"placebo-controlled":[333],"trials.":[337],"included":[340],"14,980":[341],"sporadic":[342],"14":[346],"investigating":[348],"four":[349],"mAbs:":[350],"bapineuzumab,":[351],"solanezumab,":[352],"lecanemab,":[353],"aducanumab.":[355],"To":[356],"extent,":[358],"provides":[361],"reproducible":[363],"evaluation":[364],"objective":[367],"comparison":[368],"different":[370],"interventions":[372],"AD.":[374],"application":[376],"freely":[378],"at:":[380],"https://alzmetaapp.shinyapps.io/alzmeta/":[381],"can":[383],"easily":[385],"updated":[386],"scaled":[388],"up":[389],"future.":[392],"Our":[393],"data":[394],"shows":[395],"experimental":[397],"pathology":[401],"have":[402,431,453],"been":[404],"able":[405],"significantly":[407],"memory":[409],"impairment":[410],"progression.":[413],"Initially,":[414],"were":[418,437,481,501],"small":[421,503],"molecules":[422],"interfere":[424],"metabolism.":[427],"As":[428],"shown":[432],"efficacy,":[434],"alternative":[435],"approaches":[436],"including":[442,572],"immunotherapy":[443],"modulators":[445],"removal":[448],"or":[449],"aggregation.":[450],"Anti-A\u00df":[451],"demonstrated":[454],"promising":[457],"so":[459],"far,":[460],"revealed":[467],"statistically":[471],"improved":[472],"cognitive,":[473],"functional":[474],"biomarker":[476],"outcomes.":[477],"effects":[480,500,513],"strongly":[482],"correlated":[483],"and,":[485],"therefore,":[486],"may":[487],"predicted":[489],"pathology.":[496],"However,":[497],"while":[498],"effect":[504],"sizes,":[505],"considerably":[508],"increased":[509],"risk":[510],"side":[512],"such":[514],"as":[515],"edema.":[519],"Together,":[520],"findings":[522],"indicate":[523],"treatment":[526],"still":[527],"has":[528],"many":[529],"obstacles":[530],"overcome,":[532],"risk/benefit":[535],"ratio":[536],"remains":[541],"unfavorable.":[542],"We":[543],"suggest":[544],"detection":[548],"oligomer-specific":[551],"should":[553],"accompanied":[555],"novel":[557],"pharmacological":[560],"other":[564],"processes":[565],"known":[566],"occur":[568],"AD,":[571],"abnormal":[573],"cholesterol":[574],"metabolism":[575],"neuronal":[577],"hyperexcitability":[578],"impairs":[580],"cognition,":[581],"pathology,":[583],"oxidative":[584],"stress,":[585],"epigenetic":[587]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W7199200990","counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-08-07T00:00:00"}
